In this report, we present an update of the 2020 primary systematic review, to take into account more recent evidence on the efficacy, effectiveness and safety of newer and/or enhanced seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals aged 18 years and over.
Risks of an adverse event following influenza vaccination are far less common than complications related to influenza itself, and the adverse events are generally localised and mild.
Injected trivalent inactivated influenza vaccines are most commonly used throughout the world. Influenza antigen preparation varies between manufacturers.
This report provides an integrated analysis of relationships between antimicrobial consumption in humans and food- producing animals and the occurrence of antimicrobial resistance in bacteria from humans and food- producing animals, respectively.
The aim of this survey was to review the expertise, capabilities and capacities for detection and characterisation of avian and other zoonotic influenza viruses in national influenza reference laboratories in the European Union/European Economic Area (EU/EEA), in members of the European Reference Laboratories for influenza (ERLINet), and in EU Enlargement policy countries.
Genetic and antigenic characterization data generated at the Worldwide Influenza Centre for viruses with collection dates after 31 January 2023 until 31 August 2023 informed the WHO influenza vaccine composition meeting (VCM) in September 2023 when recommendations were made for the southern hemisphere (SH) 2024 influenza season.
This report presents the results of the ninth round of the external quality assessment (EQA-9) scheme for Listeria monocytogenes (L. monocytogenes) typing, organised for national public health reference laboratories (NPHRLs) providing data to the Food- and Waterborne Diseases and Zoonoses Network (FWD-Net), managed by ECDC.